Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04843111 · ClinicalTrials.gov registry record
Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)
A clinical trial of Meningococcal Infection, sponsored by Sanofi Pasteur, a Sanofi Company.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT04843111 is a study of Meningococcal Infection that is actively recruiting participants, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 50 participants, below the 736-participant average among 3 other Meningococcal Infection trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04843111, a study of Meningococcal Infection, is actively recruiting participants, sponsored by Sanofi Pasteur, a Sanofi Company.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective: To assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women vaccinated with MenQuadfi® during pregnancy or in the 30 days preceding their Last Menstrual Period (LMP).
Conditions Studied
Interventions
- BIOLOGICAL Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine
Study Locations (1)
Pennsylvania
- Pennsylvania Locations - Swiftwater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2028-05-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04843111
The ClinicalTrials.gov registry entry for NCT04843111 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 736-participant average among 3 other Meningococcal Infection trials with a reported enrollment target (93% lower). The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Meningococcal Infection appearing as the primary indexed condition, and to 1 intervention - of which Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine is the first listed.
NCT04843111 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04843111 about?
NCT04843111 is a clinical study titled "Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)". Primary Objective: To assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women vaccinated with MenQuadfi® during pregnancy or in the 30 days preceding their Last Menstrual Period (LMP).
What is the current status of trial NCT04843111?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2021-03-05. Estimated completion is 2028-05-18.
What conditions does trial NCT04843111 study?
This clinical trial studies the following conditions: Meningococcal Infection.
What interventions are being tested in trial NCT04843111?
The interventions under investigation include: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04843111?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04843111 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningococcal Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
COMPLETED · Phase 2
-
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
COMPLETED · Phase 2
-
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.